Young Kwang Chae
Overview
Explore the profile of Young Kwang Chae including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
4672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel S, Cano-Linson E, Chae Y, Schokrpur S, Lao C, Powers B, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):24.
PMID: 39856213
We report the basal cell cancer (BCC) cohort of the SWOG/NCI 1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART), a phase II prospective, multicenter basket trial of nivolumab...
2.
Woo W, Park B, Ahadi A, Chung L, Jung C, Bharat A, et al.
J Surg Oncol
. 2024 Dec;
PMID: 39674949
Background And Objectives: Due to heterogeneous characteristics of primary cancers, the efficacy of pulmonary metastasectomy (PM) in nonprimary lung cancers has not been investigated. This study aims to investigate the...
3.
Chae Y, Othus M, Patel S, Gerber D, Tanvetyanon T, Kim H, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241293401.
PMID: 39583952
Background: Anti-programmed death-1 (PD-1)/cytotoxic T lymphocyte antigen-4 antibodies are efficacious in various malignancies. Objectives: This study presents the first results of ipilimumab-nivolumab in invasive mucinous or non-mucinous lepidic adenocarcinoma (invasive...
4.
Othus M, Patel S, Chae Y, Dietrich E, Streicher H, Sharon E, et al.
J Natl Cancer Inst
. 2024 Nov;
PMID: 39565908
Background: Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluated, with most prior research finding a positive association between toxicity and survival. This...
5.
Chae Y, Corthell L, Patel S, Edwards R, Scalici J, Kim H, et al.
Clin Cancer Res
. 2024 Nov;
31(2):308-315.
PMID: 39561273
Purpose: Dual PD-1/CTLA-4 inhibition shows promise in various malignancies. The SWOG S1609 Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) trial presents initial results of ipilimumab/nivolumab in vulvar cancers....
6.
Chae Y, Oh Y, Kim L, Park J, Djunadi T, Shah Z, et al.
Oncologist
. 2024 Nov;
PMID: 39487975
Invasive mucinous adenocarcinoma (IMA) of lung is a unique subset of adenocarcinomas characterized by an intrapulmonary aerogenous spread resulting in multicentric, multilobar, and bilateral lesions with a low frequency of...
7.
Chae Y, Othus M, Patel S, Wilkinson K, Whitman-Purves E, Lea J, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5593-5600.
PMID: 39417692
Purpose: The role of dual checkpoint inhibition (ipilimumab at 1 mg/kg intravenously every 6 weeks and nivolumab at 240 mg intravenously every 2 weeks) in advanced rare/ultrarare nonepithelial ovarian cancers...
8.
Sukhadia B, Tan D, Oh Y, Shah Z, Chae Y
JTO Clin Res Rep
. 2024 Sep;
5(10):100520.
PMID: 39346744
gain-of-function mutations cause DNA hypermethylation interfering with cellular differentiation and are linked to poor disease outcomes in NSCLC. inhibitor enasidenib is approved for refractory acute myeloid leukemia but has been...
9.
Chae Y, Othus M, Patel S, Powers B, Hsueh C, Govindarajan R, et al.
J Immunother Cancer
. 2024 Sep;
12(9).
PMID: 39343510
Background: Dual inhibition using anti-programmed death-1 (PD-1) and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) checkpoint inhibitors has proven effective in many cancers. However, its efficacy in rare solid cancers remains unclear. Desmoid...
10.
Chandrasekhar A, Yang H, Demir T, Yeldandi A, Kurihara C, Tomic R, et al.
Am J Transplant
. 2024 Sep;
25(1):209-214.
PMID: 39278626
Immunotherapy can significantly improve efficacy of cancer treatments. For locally advanced stage III lung cancers, chemoimmunotherapy in the neoadjuvant setting can achieve complete pathological response in about 40% of cases....